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Effect on Exercise Performance of Enalapril Therapy Initiated Early
After Myocardial Infarction
KENNETH DICKSTEIN, MD, PHD, TORBJORN AARSLAND, RN,* FOR THE NORDIC ENALAPRIL
EXERCISE TRIAL
Stavanger, Norway
Objectives. The Nordic Enalapril Exercise Trial was a mufti .
center subtrial of the Cooperative New Scandinavian Enalapr8
Survival Study (CONSENSUS II) designed to evaluate the effect
on maximal exercise performance of a 6-month period of enalapril
treatment Initiated early after myocardial infarction .
Ikwkgeund, When begun early after myocardial infarction,
converting enzyme inhibition therapy has been shown to attenuate
infarct expansion and reduce left ventricular volume . Therapy has
been associated with Improved exercise performance .
Methods . Three hundred twenty-seven men (mean age 63 .3 t
10.9 years) with documented acute myocardial infarction were
randomized to treatment with enalapril or placebo on a double-
blind basis. Intravenous enalaprilat or placebo therapy was
initiated within 24 h after the onset of symptoms. Oral therapy
was continued at a target dose of 20 mg/day . Patients exercised
maximally at 1 month and 6 months after infarction to symptom-
limited end points on a cycle ergometer with a 20 W/min Incre-
mental protocol.
Results. The treatment and control groups were comparable in
patient age, concurrent therapy and type and site of infarction . At
1 month, for all patients, mean total work performed was 34 .9 ±
Converting enzyme inhibition reduces peripheral vascular
resistance and has been shown to be effective in the man-
agement of symptomatic congestive heart failure (1,2) . Im-
provement in clinical status (3,4), hemodynamic status (5,6)
and exercise performance (7,8) has been demonstrated, and
therapy is associated with a reduction in mortality rate in
patients with severe congestive heart failure (9) . Two large
trials have provided convincing evidence that long-term
therapy improves prognosis in patients with moderate but
symptomatic heart failure (10,11) .
Inhibition of angiotensin-converting enzyme with capto-
pril retarded left ventricular dilation and improved survival
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20.9 kJ in the eualapril group (n = 169) versus 28 .5 ± 20.6 kJ in
the placebo group (n = 158) (difference = 18 .4%, p < 0.01). This
between-group difference In favor of enalapril was greatest In
patients >70 years old (difference = 41 .4%, p < 0.01, n = 105)
and those with clinical evidence of heart failure (difference =
33.0%, p < 0.01, u = 122) . At 6 months for all patients, mean
total work performed was 35.4 t 23.8 kJ in the enalapril group
versus 34.0 t 23.9 kJ in the placebo group (difference = 4.1%,
NS).
Conclusions . This trial found that chronic converting enzyme
inhibition initiated early after myocardial infarction was associ-
ated with significantly greater exercise capacity in men tested at I
month. This difference was independent of type or site of infarc-
tion, patient age or the presence of clinical heart failure. The
difference: between the treatment and control groups was not
significant at 6 months because of improvement in the placebo
group. Further research is needed to elucidate the potential
mechanisms involved, profile those patients most likely to profit
from early therapy and establish the optimal timing and duration
for intervention.
(J Am Coll Cardiol 1993 ;22:975-83)
in the animal model after coronary artery ligation (12) .
Recently (13), improved survival in patients with reduced
ejection fraction has been demonstrated with captopril ther-
apy initiated an average of 11 days after myocardial infarc-
tion. In patients with a Q wave anterior wall infarction,
treatment initiated during week 2 after infarction resulted in
reduced left ventricular volume on echocardiography (14,15)
and angiography (16) . This finding was accompanied by
improved exercise performance as assessed by an endurance
exercise protocol in men without exercise-induced ischemia
with an ejection fraction <45% (17) . Therapy initiated 21
days after infarction in asymptomatic patients was not
associated with improved performance (18) . However, the
effect of early initiation of long-term therapy on the func-
tional capacity of patients after myocardial infarction has not
been addressed prospectively in a large-scale trial .
Cardiac and peripheral reserve can be assessed by eval-
uating performance during maximal symptom-limited exer-
cise (19,20). Exercise testing permits objective determina-
tion of functional capacity (21) .
This technique provides a
sensitive tool for evaluating the effect of therapeutic inter-
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vention (22) .
Therapy with inotropic agents (23),
diuretic
drugs (24),
vasodilators (25) and exercise training programs
(26) has demonstrated improvement in peak and submaximal
exercise variables in patients with symptomatic heart failure
.
The Cooperative New Scandinavian Enalapril Survival
Study (CONSENSUS II) (27) was a large multicenter trial
designed to evaluate the effect on mortality at 6 months of
enalapril administered early after myocardial infarction
. The
Nordic Enalapril Exercise Trial was a CONSENSUS II
subtrbtl designed to test the hypothesis that long-term con-
verting enzyme inhibition initiated in patients early after
myocardial infarction would improve exercise performance .
Three hundred twenty-seven men with documented acute
myocardial infarction were randomized in a double-blind
manner to enalapril or placebo according to the CONSEN-
SUS 11 protocol previously reported (27) . Patients were
tested at I and 6 months using a maximal, symptom-limited,
incremental exercise protocol .
Methods
Study protocol, The Nordic Enalapril Exercise Trial was
prospectively designed in connection with the CONSEN-
SUS 11 study. Eleven hospitals in Scandinavia participated
in this subtrial (Appendix) . Patients randomized into the
CONSENSUS II study were invited to participate .
Myocardial infarction was confirmed by conventional
clinical, electrocardiographic (ECG) and biochemical crite-
ria. Therapy was initiated within 24 h after the onset of chest
pain with intravenous enalaprilat (I mg1250 ml, 5% dextrose
in water) or placebo administered over 3 h. Arterial blood
pressure was monitored continuously, and therapy was
discontinued if systolic blood pressure decreased to
<90 mm Hg. Oral therapy was initiated 6 h after the
completion of the infusion with 2 .3 mg of enalapril or
placebo. The dosage was titrated to 20 mg daily in the
absence of possible drug-related side effects, symptomatic
hypotension or a substantial increase in serum creatinine .
Other therapy, administered concurrently as clinically indi-
cated for the management of acute myocardial infarction,
Included tbrombolytic therapy and intravenous administra-
tion of nitroglycerin and beta-adrenergic blocking agents .
The protocol specified that patients whose clinical condition
deteriorated to Now York Heart Association functional class
IV should be withdrawn from the trial and placed on open
Label therapy .
Patients were included consecutively in the exercise trial
I month after myocardial infarction. However, we excluded
candidates who were considered to be in clinically unstable
condition or were unable to perform a maximal, symptom-
limited exercise test . Concurrent medication at l month is
listed for both the treatment and the placebo groups in Table 1 .
Study pttialL Patients with an onset of chest pain <24 h
before hospital admission were screened for possible inclu-
sion into the CONSENSUS II study. Eligible patients with
significant aortic stenosis, hypotension (systolic blood pres-
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myocardial infarction: SBP = systolic
blood pressure .
sure < 105 mm Hg), cardiogenic shock or need for inotropic
support were not randomized. Patients considered by the
investigator to be unable to perform maximal exercise at
1 month were not included in the trial .
Three hundred twenty-seven men with documented myo-
cardial infarction were included in the study . The mean age
was 63.3 ± 10.9 years. Patients were concurrently treated
with all other clinically indicated medication apart from
converting enzyme inhibition therapy . Two hundred nine
patients had ECG evidence of Q wave myocardial infarction,
and 136 patients showed evidence of anterior myocardial
infarction. Eighty-four patients had previous confirmed
myocardial infarction, and 105 patients were a!70 years old .
A detailed description of the clinical characteristics of the
study group according to randomization is provided in Table 1 .
Exercise testing protocol. The exercise protocol em-
ployed an upright, electronically braked cycle ergometer and
was based on an initial work load of 20 W, with stepwise
20-W increments at 1-min intervals . Testing occulted ap-
proximately 2 h after a light meal and always between 2 and
6 h after ingestion of the test medication. Patients were
instructed to maintain a pedaling rate of approximately 65 rpm
and to exercise maximally to symptomatic end points, re-
sulting in the inability to maintain constant pedal speed . A
12-lead ECG was interfaced, and heart rate was recorded
continuously .
Total exercise duration was recorded from the start of
exercise to the point where the patient was unable to
maintain a constant pedaling speed . Total work performed
was calculated in joules . Peak heart rate and the magnitude
of ST segment depression were recorded . The primary
symptom causing the patient to discontinue exercise and
other concurrent symptoms were noted .
Table 1
. Clinical Characteristics at I Month
Placebo
(a = 158)
Enalapril
(n = 169)
Age (yr)
63 .4 *_ 11 .3 63.2 t 10.8
Previous MI (%)
24 21
Peak CK-MB (U/liter) 172 ± 134
173 t 143
Q wave MI (%)
61
67
Non-Q wave MI (%)
39 33
Anterior Ml (%)
44 42
Non-anterior MI (%) 56
58
Rest SBP (mm Hg) 135
± 22 130 t 23*
Rest DBP (mm Hg) 82
± 11 79 :t lit
Concurrent therapy (%)
Thrombolytic agents
54 664
Digitalis
9 6
Diuretics
13
18
Beta-blocking agents 57 53
Calcium channel blockers 10
9
Nitrates 25
25
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Statistical methods. The Fisher exact test was used to
compare the treatment groups with respect to dichotomous
variables. The Wilcoxon rank sum test was used to compare
treatment groups with respect to ordinal variables . Differ-
ences between the treatment groups with respect to contin-
uous variables were tested using nonparametric analysis of
covariance models. The rank sum test was used to compare
the treatment groups and the signed rank test to test within-
group differences .
Results
Three hundred twenty-seven men were included in the
exercise trial . One hundred sixty-nine patients were random-
ized to enalapril and 158 patients to placebo . The average
long-term dose of enalapril was 18 .7 mg and of placebo,
19.1 mg. Five hundred folly-one men. were randomized into
the CONSENSUS 11 study at the II centers during the
period of inclusion into the Nordic Enalapril Exercise Trial .
One hundred forty-seven patients were considered by the
investigator unable to perform maximal exercise at I month
largely because of unstable angina pectoris, advanced age or
orthopedic conditions. Sixty-seven patients (37 receiving
enalapril, 30 receiving placebo) died before the first exercise
test, and 22 patients died between I and 6 months (10
receiving enalapril, 12 receiving placebo) . Sixteen patients (6
receiving enalapril, 10 receiving placebo) underwent coro-
nary artery bypass grafting or percutaneous ttansluminal
coronary angioplasty between I and 6 months and were
excluded from the 6-month Nordic Enalapril Exercise Trial
test as per protocol .
The treatment groups were comparable with regard to
age, concurrent therapy at I month and type and site of
myocardial infarction (Table 1) . Both mean systolic and
diastolic blood pressure at rest were significantly lower in
the enalapril group (p < 0 .01). A small but significant
difference (p < 0.05) in thrombolytic therapy during the
acute phase of infarction was noted . The mean peak creatine
kinase, MB fraction was 172 ± 134 Ulliter in the placebo
group and 173 ± 143 Ulliter in the enalapril group .
Exercise performance . Peak heart rate during exercise at
I month in the placebo group was 128 ± 22 versus 132 t 24
beats/min in the enalapril group (p = NS). At 6 months, peak
heart rate in the placebo group was 132 ± 22 versus 130 t 26
beats/min in the enalapril group (p = NS) . There were no
significant between group differences at either I or 6 months
with regard to the major limiting symptom at the termination
of exercise (Table 2) .
At I month for all patients, mean total work performed in
the enalapril group was 34.9 ± 20 .9 versus 28 .5 ± 20 .6 kJ in
the placebo group (difference = 18 .4%, p < 0.01). At 6
months, mean total work performed in the enalapril group
was 35 .4 ± 23 .8 versus 34.0 ± 23 .9 kJ in the placebo group
(difference = 4.1%, p = NS) . The results are shown for both
work performed and total exercise duration in Tables 3
and 4 .
Subgroup analysis. Four subgroups were prospectively
defined for analysis . Patients were classified into groups
according to myocardial infarction type (Q wave vs . non-Q
wave), site of myocardial infarction (anterior vs . nonante-
rior), age (<70 vs . ?70 years) and heart failure, as indicated
by the presence of at least two of the following criteria at I
month: diuretic therapy, pulmonary rales, peripheral edema
or cardiomegaly by two-plane chest X-ray film (28) (relative
volume >600 ml/m) .
The percent between-group differences at I and 6 months
Figure 1 . Work performed at 1 and 6 months after myocardial
infarction (Ml) in the placebo and enalapril groups . Values are
expressed as mean value (kilojoules [kJ]) ± SEM .
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Table 2 . Primary Reason for Termination of Exercise in the
Enalapril to = 169) and Placebo (n = 158) Groups
977
Symptoms I Month 6 Months
Chest pain (%%I
Placebo 18 8
Enalapril 15 12
Dyspnea (%)
Placebo 28 20
Enalapril 25 16
Exhaustion ( 1
Placebo 40 56
Enalapril 48 58
ST segment depression (7 )
Placebo 6 5
Enalapril 5 5
Arrhythmia 04 )
Placebo I 0
I;nal .tprii 1 1
Hypatensia,n ( )
Placebo 3 1
Enalapril 3 1
Oilier M
Placebo 4 10
Enalapril 3 7
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Tam 3. A Summary of Peak Exercise Performance at I Month
Placebo
Abbreviations as in Table 3
.
in work performed for patients with anterior myocardial
infarction were 23.2% (enalapril > placebo, p = NS) and
5.8% (enalapril > placebo, p = NS), respectively. The
corresponding percent differences for nonanterior myocar-
dial infarction were 21 .4% (enalapril > placebo, p < 0.05)
and 1,896 (enalapril > placebo, p = NS) (Fig. 2).
The percent between-group , differences at l and 6 months
in work performed for patients with Q wave myocardial
infarction were 9.0% (enalapril > placebo, p = NS) and 1.8%
(placebo > enalapril, p - NS), respectively . The corre-
sponding differences for non-Q wave myocardial infarction
were 46.3% (enalapril > placebo, p < 0 .01) and 20.2%
(enalapril > placebo, p = NS) (Fig . 3).
The percentage between-group differences at I and 6
months in work performed for patients <70 years old were
14.496 (enalapril > placebo, p = NS) and 5 .5% (enalapril >
placebo, p - NS), respectively. The corresponding percent
differences for patients 00 years old were 41 .4% (enalapril
> placebo, p < 0.01) and 16.996 (enalapril > placebo, p =
NS): (Fig. 4).
The percent between-group differences at I and 6 months
in work performed for patients with clinical evidence of
heart f iiure were 33.0% (enalapril > placebo, p < 0.01) and
2.7% (placebo > enalapril, p = NS), respectively. The
corresponding percent differences for patients without heart
Time (s)
Enalep it
'p < 0.01
. tp < 0
.05 . All values are expressed as mean value
t SD. kJ - kilo pules . MI
a
myocardial infarction .
Table 4. A Summary of Peak Exercise Performance at 6 Months
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failure were 18 .0% (enalapril > placebo, p = 0.05) and 8.7%
(enalapril > placebo, p = NS) (Fig . 5) .
Possible subgroup interactions (myocardial infarction
type, localization, age and heart failure) were tested with a
nonparametric analysis of variance model and none were
significant, indicating that the effect of enalapril versus
placebo was consistent across the subgroups .
Discussion
Maximal exercise testing has been shown to be a valuable
tool in the clinical assessment of functional capacity (21) and
prognosis (20). It has been demonstrated that peak exercise
performance with metabolic evidence of anaerobiosis can be
achieved reliably in patients with coronary artery disease
(29,30). The results are highly reproducible in such patients
l month after myocardial infarction (31) . Measurements of
exercise capacity provide clinically relevant information
with regard to functional status and should not be considered
as surrogate end points in cardiac evaluation .
Converting enzyme Inhibition and exercise capacity. Con-
vincing evidence exists confirming symptomatic and func-
tional improvement in patients with New York Heart Asso-
ciation functional class III and IV heart failure treated with
converting enzyme inhibitors (32) . The renin-angiotensin
Placebo
Work (kJ)
Enalaprl Difference (%)
Time (s) Work (kJ)
Placebo Enalapril Placebo
Enalapril Difference (%)
All patients 384 ± 129
428 ± 121 29.52 20 .6 34.9 ± 20 .9 +18 .4*
Anterior MI 380 t 126 426 ± 116
28.0 t 20.0 34.5 t 19 .8 +23 .2
Nonaolerior Mt 387 ± 132
430 t 124 29.0 t 21 .3 35.2 ± 21 .5 +21 .4t
Q.wavt MI 416 ± 118 436 ± 118 33.1 t 20
.0 36.1 ± 20 .7 +9.0
Non.Q.wave MI 352 ± 134 431 ± Ill 24
.2 t 20 .1 35.4 S 20.2 +46.3"
<70 yr 436 t 113 469 t III
36.2 t 10 .5 41,4 ± 12 .7 +14 .4
a70 yr Min 341
t 92 16.2 t 20 .1 22.9 ± 20 .6 +41 .4'
No heart failure 407 1128 445 ± 123 31 .8 t 21.3 37
.5 t 22 .0 +18 .0
Heart failure 344 t 123 401 t 113 23.3 t 17 .8
31 .0 ± 18 .4 +33 .0'
AD patients 423
1
137 432 ± 135 34.0 ± 23 .9 35 .4 t 23.8 +4 .1
Anterior hit 426
2: 131 439 t 130 34.6±22 .8 36.6 ± 23.1 +5 .8
Nonanterior MI 423 t 124 426 ± 139 34.0 24.9 34.6 24.5 +1 .8
Q.wave MI 449 t 140 444 ± 128 38 .1 t 25 .5 37.4 ± 22.9 -1 .8
Non4wave M1 381 ± 124 422 t 145 28 .2 ± 19.5 33 .9 ± 25.6 +20.2
<70 yr 472 ± 124 486 t 124 42 .0 ± 12.3 44.3 ± 13.6 +5 .5
a70 yr 313 t 94 340 t 97 19 .5 ± 23 .2 22 .8 ± 24.0 +16.9
No hart faikire C6 t 143 455 t 142 36 .1 ± 25.6 391 ± 26.1 +8 .7
heart failure 399 ± 122 393 t 114 30.6 ± 19.8 29.8 ± 18.1 -2 .7
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Figure 2. Work performed at I and 6 months
after myocardial infarction (MI) in the pla-
cebo and enalapril groups according to infarct
type. Values are expressed as mean value
(kilojoules (kJ]) ± SEM .
Figure 3. 'York performed at I and 6 months
after myocardial infarction (Ml) in the pla-
cebo and enalapril groups according to infarct
she. Values are expressed as mean value
(kilojoules [kJ]) t SEM.
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system is markedly activated during both moderate and
strenuous exercise in patients with heart failure (33,34) . This
response may contribute substantially to the attenuated
vasodilator reserve in skeletal muscle observed in patients
with heart failure (35,36) . Converting enzyme inhibition may
partially correct this pathophysiologic response, improve
vasodilator reserve and increase muscle blood flow (37-39) .
Long-term therapy has been shown to attenuate the marked
increase in adrenergic tone that accompanies maximal exer-
cise in patients with left ventricular dysfunction (40) .
The results of this trial indicate that enalapril therapy
initiated early after myocardial infarction is associated with
improved exercise capacity during the convalescent phase .
The difference in work performed at I month was 18 .4% (p <
0.01) between the active and control group for all patients .
The difference was greatest for patients a70 years old
(41 .4%, p < 0.01), for patients with non-Q-wave myocardial
infarction (46,3%, p < 0 .01), and for patients with clinical
evidence of heart failure (33 .0%, p < 0 .01) . The difference in
47 .0
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Months post-MI Months post-MI
work performed at 6 months was 4 .1% (p = NS) for all
patients .
The results are expressed in units of work performed
because testing involved a rapidly increasing incremental
protocol, as opposed to an endurance protocol in which
exercise duration would be the most appropriate variable .
Differences between the treatment groups were tested using
nonparametric analysis of covariance models, so that the
statistical significance of observed differences is identical for
both time and work . The four subgroups were identified
prospectively in an attempt to identify the group most likely
to profit from intervention . Although no subgroup interac-
tions were found to be significant . the power of tests for
interaction was limited, and the data do suggest a degree of
subgroup interaction .
Potential mechanisms . The potential mechanisms respon-
sible for these ibservations are not known, and we can only
speculate about the possible physiologic factors involved .
This trial did not measure central or peripheral hemodynam-
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ics, or d neurohumoral status was not assessed . It is postu-
lated that the findings in this trial probably result from both
an attenuation of ventricular dilation after myocardial infarc-
tion and a reduction of the increased peripheral vascular
resistance associated with deconditioning and left ventricu-
lar dysfunction .
Several studies have demonstrated that converting en-
zyme inhibition initiated early after myocardial infarction
attenuates left ventricular dilation by means of reduction of
infarct expansion and improved remodeling of noninfarcted
myocardium (15,16,41). A subtrial of the CONSENSUS 11
study also confirmed that enalapril therapy initiated during
the acute phase after myocardial infarction was associated
with reduced left ventricular volumes at both I and 6 months
(42). The largest difference in volumes was observed at t
month. It is certainly conceivable that attenuated left ven-
tricular dilation during the convalescent phase may be
relevant to the interpretation of the results,
The convalescent phase after acute myocardial infarction
Months post-Ml
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Figure 4. Work performed at I and 6 months
after myocardial intrction (MI) in the pta •
cebo and enalapril groups according to age
<70 years or a70 years. Values are expressed
as mean value (kilojouies [h1]) ± SEM .
is associated with reduced exercise performance due to both
a reduction in cardiac reserve and prolonged inactivity with
deconditioning (43). reconditioning is associated with atten-
uated vasodilator capacity in skeletal muscle . This is largely
due to interstitial and intramural salt and water retention, as
well as a reduction in vessel size resulting from reduced
muscular blood flow (44,45) . In the presence of heart failure,
neurohumoral activation also contributes to elevated periph-
eral vascular resistance (35).
It has been demonstrated that activation of the renin-
angiotensin-aldosterone system is largely limited to the acute
and early convalescent phase and persists only in patients
with sustained left ventricular failure after myocardial infarc-
tion (46) . No data are available that describe the degree of
activation during the later convalescent phase (47) . We did
not measure plasma renin activity during this trial because
half of the patients were randomized to an angiotensin-
converting enzyme inhibitor. Considering the selection bias
in this trial, it is reasonable to postulate that most patients
Figure 5. Work performed at I and 6 months
after myocardial infarction (MI) in the pla-
cebo and enalapril groups according to the
presence or absence of clinical evidence of
heart failure. Values are expressed as mean
value (kilojoules [kJ]) ± SEM .
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did not have substantial neurohumoral activation at the
6-month test .
The improved exercise performance in the placebo group
at 6 months is compatible with previous reports demon-
strating improvement in exercise performance observed
during the 1st 6 months after myocardial infarction (43,
48). This is probably the result of both improved ventric-
ular performance and reversal of the modest decondition-
ing process associated with the convalescent phase after
myocardial infarction . The similarity in performance be-
tween groups at 6 months was due to improvement in
the placebo group and not to deterioration in the enalapril
group.
Limitations of the study. The trial has some important
limitations . The patient group was selected both by protocol
design and by practical considerations . The CONSENSUS
II protocol excluded patients with hypotension, cardiogenic
shock, need for inotropic support or concurrent converting
enzyme inhibitor therapy . Patients who developed symp-
toms of heart failure at rest were withdrawn from the trial in
favor of open label therapy . Furthermore, the NES'proto-
col excluded patients considered unable to perform a maxi-
mal exercise test at I month . These considerations would
tend to exclude the patients most likely to develop sustained
left ventricular dysfunction, that is, the subgroup most likely
to profit from intervention .
Most trials demonstrating improvement in exercise per-
formance with converting enzyme inhibition have shown the
greatest improvement in the most symptomatic patients
receiving long-term therapy (17,49), Information regarding
ejection fraction or the severity of focal hypokinesia and left
ventricular dilation was not available in the present trial .
Assessment of the presence of heart failure was based on
commonly available clinical criteria . Considering that both
the CONSENSUS lI and NEET protocols excluded the
most seriously ill patients, it is likely that most patients in
this trial were comparatively well compensated hemodynam-
ically with only mild left ventricular dysfunction . Therefore,
this selection bias would suggest that therapy might be even
more efficacious when the more symptomatic postinfarction
patients are targeted. This hypothesis deserves further in-
vestigation .
Trials evaluating acute therapy after myocardial infarc-
tion cannot establish a stable baseline before intervention .
Assessment of the comparability between the randomized
groups is therefore essential . In this trial, the groups were
comparable with regard to age, concurrent therapy and
type and site of myocardial infarction . There was a small
but significant difference with regard to thrombolytic
therapy during the index infarction . The enalapril group
contained the larger percentage (66% vs. 54%); however,
the mean peak myocardial creatine kinase release was
identical for the two groups . Theoretically, thrombolytic
therapy might reduce infarct size and permit improved
peak exercise performance. A recent report (50) did
demonstrate a 15% (p < 0.05) improvement in exercise
DICKSTEIN AND AARSLAND
EFFECT OF ENALAPRIL ON EXERCISE PERFORMANCE
981
duration at 3 months
. However, the similarity in exercise
performance in our trial at 6 months suggests that the groups
were comparable and that the difference in performance
observed at I month was therefore not the result of selection
bias .
This trial does not address the issue of the optimal timing
of initiation of converting enzyme inhibition therapy after
myocardial infarction. All patients were randomized accord-
ing to the CONSENSUS II protocol with therapy initiated
within the 1st 24 h . It may be that the improved performance
at I month would have been observed had oral therapy been
initiated at a late, stage during the convalescent phase . Such
an approach we Jld permit inclusion of the considerable
group of patients with hypotension obviating initiation of
therapy in the acute phase .
Implications . Improvement in exercise capacity during
the early convalescent phase after acute myocardial infarc-
tion has practical clinical consequences . Such improvement
would serve to facilitate rehabilitation aimed at reversal of
the deconditioning process and permit earlier resumption of
normal physical activity . However, the cost and potential
adverse effects of generalized use of converting enzyme
inhibition after myocardial infarction are substantial . Fur-
ther research should attempt to elucidate the physiologic
mechanisms involved, profile the patient group most
likely to profit from early therapy and establish the op-
timal timing and duration for intervention . The advantages
of a more rapid recovery after myocardial infarction are
considerable .
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